Immutep (IMMP) Stock Price, Quote, News & History | Benzinga

Immutep Ltd (IMMP) Stock Price, Quote, News & History

IMMPNASDAQ

Trade with Public

Trade with Public

$0.3911

-0.0022-0.56%

At close: Aug 20, 5:00 PM EST

$0.3910

-0.0001-0.03%

After Hours: 7:56 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Compare Options Stock Report

Key Statistics

Open

$0.40

Close

$0.39

Volume / Avg.

81.27K / 455.62K

Day Range

$0.38 - $0.40

52 Wk Range

0.29 - 3.53

Market Cap

$57.55M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

49

Short Interest

0.83%

Days to Cover

5.44

Recent Immutep Ltd News

Nasdaq Surges 200 Points; Morgan Stanley Posts Upbeat Earnings

US stocks rise, Nasdaq up 200 points; Tech shares lead gains. Morgan Stanley beats estimates. Allbirds up 349%, Snap up 6%. Oil rises 0.7%, gold up 0.1%.

Avi Kapoor

Immutep Gets FDA Boost For Lead Cancer Drug, Stock Doubles

Immutep stock jumps after FDA orphan drug tag for eftilagimod alfa, even as halted Phase 3 trial and mixed analyst views weigh on outlook.

Vandana Singh

Dow Gains 100 Points; Bank of America Earnings Top Views

US stocks up on Wed, Dow +0.22%, NASDAQ +0.37%, S&P 500 +0.28%. Bank of America beats Q1 earnings. Allbirds Inc. shares soar 323%.

Avi Kapoor

Why NN Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket

NN Inc. (NNBR) rose in pre-market trading after announcing expected sales growth and raising full-year guidance. Other gainers include NICM, AGAE, IMMP, LIMN, CIIT, MLSS, LAES, GBR, and STNE. Losers include SNAL, MIMI, ARAI, and SURG.

Avi Kapoor

Immutep Stock Tanks After Futility Analysis Ends Key Lung Cancer Trial Early

Immutep announced the discontinuation of the TACTI-004 Phase 3 trial. The CEO expresses disappointment. Stock down 80.62% to $0.53.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-

Investing Cash Flow (TTM)

27.22M

Financing Cash Flow (TTM)

-186.12K

Free Cash Flow (TTM)

-33.35M

Capital Expenditure (TTM)

-138.18K

Net Change in Cash (TTM)

-9.51M

Analyst Trends and Forecast

0

0

0

0

Feb

2

Mar

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

-$13.06M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

0.82

Earnings Yield % (TTM)

-

Earnings Yield % (FWD)

-51.85%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.48

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-$270.67K

Total Cash

-

Debt to Equity

0.01

Issuance of Debt (TTM)

-$270.67K

Repayment of Debt (TTM)

-$270.67K

Key Statistics

Open

$0.40

Close

$0.39

Volume / Avg.

81.27K / 455.62K

Day Range

$0.38 - $0.40

52 Wk Range

0.29 - 3.53

Market Cap

$57.55M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

49

Short Interest

0.83%

Days to Cover

5.44

About

Sector

Health Care

Industry

Biotechnology

Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stim...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Immutep (IMMP) stock?

A

You can purchase shares of Immutep (NASDAQ:IMMP) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Immutep (IMMP) competitors?

A

There are no as such competitors for Immutep.

Q

What is the forecast, or price target, for Immutep (IMMP) stock?

A

Immutep has a consensus price target of $7.00.

Q

What is the current price for Immutep (IMMP)?

A

The stock price for Immutep (NASDAQ: IMMP) is $0.391 last updated August 20, 2026 at 7:56 PM EDT.

Q

Does Immutep (IMMP) pay a dividend?

A

There are no upcoming dividends for Immutep.

Q

When is Immutep (NASDAQ:IMMP) reporting earnings?

A

Immutep does not have any upcoming earnings scheduled.

Q

Is Immutep (IMMP) going to split?

A

There is no upcoming split for Immutep.

Q

What sector and industry does Immutep (IMMP) operate in?

A

Immutep is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.